The average one-year price target for Beam Therapeutics (BMV:BEAM) has been revised to MX$839.72 / share. This is a decrease of 13.38% from the prior estimate of MX$969.43 dated September 13, 2026.

The average one-year price target for Immutep (ASX:IMM) has been revised to $0.50 / share as of September 29, 2026. This is a decrease of 46.20% from the prior estimate of $0.94 dated September 11, ...

Inmunova’s pioneering drug could become the first specific treatment for a disease that mainly affects children ...

Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund falling 1.89% ...

Novonesis has completed its acquisition of Australian biotechnology company MicroBioGen, strengthening its expertise in yeast ...

Spiber Inc., a bio-venture from Tsuruoka City, Yamagata Prefecture, is garnering significant attention as an innovation in ...

Devendra Fadnavis said Maharashtra will expand Marathi use in AI, quantum computing, space technology and biotechnology. The ...

In a previous column, “Identifying dyslexia in Malaysian schools and learning to cope,” I highlighted a quiet crisis in our ...

Rawlings, the Minister of Environment, Science, Technology and Innovation, has called for stronger collaboration between the ...

Which Drugs and Pharma Shaped Oncology in the First Half of 2026? Breaking Down FDA Approvals / BIGR, FDA, OncoDaily, ...

UCN and Colorado School of Mines signed a five-year sustainable mining research partnership on 1 October 2026, spanning four ...

Bhopal: Madhya Pradesh Chief Minister Dr Mohan Yadav on October 3 laid the foundation stone for the Advanced Technology and ...